Clinical trial · Observational
Evaluation of the RESTART Survival Programme
NCT06283511CI-TRIAL-00086622not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022. In this project, investigators are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Invasive Breast Cancer | Invasive Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| educational workshops | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Assessment of satisfaction with participation in the Restart programme and its various components via Likert scale and open questions.
- timeFrame
- 1 month after end of programme and 12 months after end of the programme
- description
- To assess the global satisfaction with participation in the Restart programme and its various components via the Likert Scale.
Secondary outcomes (10)
- measure
- assessment of quality of life
- timeFrame
- baseline - 1 month after end of programme - 12 months after end of programme
- description
- To measure changes in quality of life via EORTC30 questionnaire
- measure
- assessemnt of health literacy via HLQ questionnaire
- timeFrame
- baseline - 1 month after end of programme - 12 months after end of programme
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \>= 18 at the time of signing the ICF 2. Minimum understanding of French 3. Signed study informed consent form obtained prior to any study-related procedure. 4. Participation in the RESTART programme 5. Patient with curative breast cancer (AJCC stage I-II-III) Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.